|
|
|
|
LEADER |
00000cam a2200000 i 4500 |
001 |
SCIDIR_ocn643604689 |
003 |
OCoLC |
005 |
20231117033144.0 |
006 |
m o d |
007 |
cr bn||||||abp |
007 |
cr bn||||||ada |
008 |
100625s1979 enka ob 101 0 eng d |
040 |
|
|
|a OCLCE
|b eng
|e pn
|c OCLCE
|d OCLCQ
|d OCLCO
|d UIU
|d OCLCQ
|d OCLCF
|d OCLCO
|d IDEBK
|d N$T
|d E7B
|d EBLCP
|d HEBIS
|d DEBSZ
|d OCLCO
|d OCL
|d OCLCO
|d OCLCQ
|d OCLCO
|d YDXCP
|d OCLCQ
|d OCLCO
|d OCLCQ
|d MERUC
|d OCLCO
|d OCLCQ
|d STF
|d OCLCO
|d OCLCA
|d OCLCQ
|d VLY
|d OCLCQ
|d OCLCO
|d COM
|d OCLCO
|d OCL
|d OCLCQ
|d OCLCO
|
019 |
|
|
|a 608588882
|a 896795235
|a 974615224
|a 974670504
|a 1162539819
|
020 |
|
|
|a 9781483154756
|q (electronic bk.)
|
020 |
|
|
|a 1483154750
|q (electronic bk.)
|
020 |
|
|
|z 0080231926
|
020 |
|
|
|z 9780080231921
|
035 |
|
|
|a (OCoLC)643604689
|z (OCoLC)608588882
|z (OCoLC)896795235
|z (OCoLC)974615224
|z (OCoLC)974670504
|z (OCoLC)1162539819
|
042 |
|
|
|a dlr
|
050 |
|
4 |
|a QP364.7
|b .N483 1979
|
060 |
|
4 |
|a W3
|b IN54R 7th 1978a v.2
|
060 |
|
4 |
|a QV 126
|b I61 1978n
|
072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
072 |
|
7 |
|a MED
|x 075000
|2 bisacsh
|
072 |
|
7 |
|a SCI
|x 036000
|2 bisacsh
|
082 |
0 |
4 |
|a 615/.1/08 s
|a 612/.8/042
|
245 |
0 |
0 |
|a Neurotransmitters :
|b proceedings of the 7th International Congress of Pharmacology, Paris 1978 /
|c editor, P. Simon.
|
250 |
|
|
|a 1st ed.
|
260 |
|
|
|a Oxford ;
|a New York :
|b Pergamon Press,
|c 1979.
|
300 |
|
|
|a 1 online resource (x, 302 pages) :
|b illustrations
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
1 |
|
|a Advances in pharmacology and therapeutics ;
|v v. 2
|
504 |
|
|
|a Includes bibliographical references and index.
|
506 |
|
|
|3 Use copy
|f Restrictions unspecified
|2 star
|5 MiAaHDL
|
533 |
|
|
|a Electronic reproduction.
|b [Place of publication not identified] :
|c HathiTrust Digital Library,
|d 2010.
|5 MiAaHDL
|
538 |
|
|
|a Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002.
|u http://purl.oclc.org/DLF/benchrepro0212
|5 MiAaHDL
|
583 |
1 |
|
|a digitized
|c 2010
|h HathiTrust Digital Library
|l committed to preserve
|2 pda
|5 MiAaHDL
|
588 |
0 |
|
|a Print version record.
|
505 |
0 |
|
|a Front Cover; Neurotransmitters; Copyright Page; Table of Contents; Introduction; Part I: GABA: Simple Molecule With Complex Functions; Chapter 1. GABA Systems in Human Brain in Huntington's Disease and Schizophrenia; GABA RECEPTOR BINDING IN HUMAN BRAIN; GAD IN HUMAN POST-MORTEM BRAIN IN HUNTINGTON'S DISEASE AND SCHIZOPHRENIA; CONCLUSIONS; REFERENCES; Chapter 2. Stereospecific Actions of GABA Analogues; INTRODUCTION; NEURONAL RECEPTORS FOR GABA IN THE CNS; UPTAKE SYSTEMS FOR GABA IN THE CNS; CYCLOPENTANE ANALOGUES OF GABA; 'ACTIVE CONFORMATIONS' OF GABA; CONCLUSION; REFERENCES; Acknowledgement.
|
505 |
8 |
|
|a Chapter 3. Barbiturates, Benzodiazepines and the GABA SystemThe effects on GABA-mediated synaptic inhibition; CNS depressants and GABA release; Direct GABA-like effects of depressant drugs; Effects of depressants on responses to GABA; Effects of depressants on GABA antagonists; ACKNOWLEDGEMENTS; REFERENCES; Chapter 4. Kinetics of GABA Action at the Crayfish Neuromuscular Junction; REFERENCES; Chapter 5.A Molecular Mechanism for the Action of Benzodiazepines on GABAergic Transmission; Evidence for the interaction of BZDs with GABA mechanisms.
|
505 |
8 |
|
|a Mechanisms by which BZD enhances GABAergic transmissionPresence of a protein modulator of the Na+-independent GABA binding in crude synaptic membranes prepared from brain; Interaction between BZDs and the endogenous modulator of the Na+- independent high affinity site for GABA; The supramolecular nature of GABA postsynaptic receptors: identification of components; REFERENCES; Chapter 6. Toward a Rational Pharmacology of the GABA System; ABSTRACT; INTRODUCTION; IDENTIFYING GABA-RELEASING NEURONS IN THE VERTEBRATE CNS; GABA NEURONS PARTICIPATE IN NUMEROUS AND COMPLEX RELATIONS.
|
505 |
8 |
|
|a GABA NEURONS AND FUNCTIONAL COORDINATIONGABA ACTION AND DEACTIVATION: AGONISTS, ANTAGONISTS, AND AMPLIFIERS; STRUCTURE-ACTIVITY RELATIONS; PROPOSED COUPLED ACTION-INACTIVATION MECHANISM OF GABA FUNCTION; CONCLUDING REMARKS; REFERENCES; Part II: Interdependence of Neurotransmitter Systems in the CNS; Chapter 7. Physiology and Pharmacology of Ganglionic Synapses as Models for Central Transmission; INTRODUCTION; INTRASYNAPTIC MECHANISMS; INTERSYNAPTIC MECHANISMS; MODULATION OF GANGLIONIC TRANSMISSION BY ENDOGENOUS COMPOUNDS; CONCLUSIONS; Acknowledgment; REFERENCES.
|
505 |
8 |
|
|a Chapter 8. Microphysiological and Pharmacological Studies on Transmitters in the Substantia NigraGABA; REFERENCES; Chapter 9. Studies of the Interdependence of Neurotransmitter Systems by Microbiochemical Approaches; Introduction; Measurement of rates of neurotransmitter utilization as a research tool in neurochemical pharmacology; Relationship between nerve stimulation and the turnover rate of ACh and GABA in identified neuronal pathways; Studies on the dopaminergic regulation of GABAergic and cholinergic neurons fby measurements of TRACh and TRGABA in brain nuclei.
|
520 |
|
|
|a Advances in Pharmacology and Therapeutics, Volume 2: Neurotransmitters contains the proceedings of the 7th International Congress of Pharmacology held in Paris, France, in 1978. The papers explore advances in the understanding of neurotransmitters, their pharmacology, and their therapeutic applications. Topics covered range from the functions of GABA to the interdependence of neurotransmitter systems in the central nervous system (CNS). This volume is comprised of 24 chapters and opens with a discussion on the role of GABA systems in Huntington's disease and schizophrenia. The reader is then.
|
546 |
|
|
|a English.
|
650 |
|
0 |
|a Neurotransmitters
|v Congresses.
|
650 |
|
0 |
|a Aminobutyric acid.
|
650 |
|
0 |
|a Neurotransmitters.
|
650 |
|
0 |
|a Neurotransmitters
|x Congresses.
|
650 |
|
2 |
|a Aminobutyrates
|0 (DNLM)D000613
|
650 |
|
2 |
|a Neurotransmitter Agents
|0 (DNLM)D018377
|
650 |
|
6 |
|a Neurotransmetteurs
|0 (CaQQLa)201-0006023
|x Congr�es.
|0 (CaQQLa)201-0378208
|
650 |
|
6 |
|a Neurotransmetteurs
|0 (CaQQLa)201-0006023
|v Congr�es.
|0 (CaQQLa)201-0378219
|
650 |
|
6 |
|a Acide aminobutyrique.
|0 (CaQQLa)201-0077072
|
650 |
|
6 |
|a Neurotransmetteurs.
|0 (CaQQLa)201-0006023
|
650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
650 |
|
7 |
|a MEDICAL
|x Physiology.
|2 bisacsh
|
650 |
|
7 |
|a SCIENCE
|x Life Sciences
|x Human Anatomy & Physiology.
|2 bisacsh
|
650 |
|
7 |
|a Aminobutyric acid
|2 fast
|0 (OCoLC)fst00807656
|
650 |
|
7 |
|a Neurotransmitters
|2 fast
|0 (OCoLC)fst01036566
|
655 |
|
2 |
|a Congress
|0 (DNLM)D016423
|
655 |
|
7 |
|a proceedings (reports)
|2 aat
|0 (CStmoGRI)aatgf300027316
|
655 |
|
7 |
|a Conference papers and proceedings
|2 fast
|0 (OCoLC)fst01423772
|
655 |
|
7 |
|a Conference papers and proceedings.
|2 lcgft
|
655 |
|
7 |
|a Actes de congr�es.
|2 rvmgf
|0 (CaQQLa)RVMGF-000001049
|
700 |
1 |
|
|a Simon, Pierre,
|d active 1970-
|
711 |
2 |
|
|a International Congress of Pharmacology
|n (7th :
|d 1978 :
|c Paris, France)
|
776 |
0 |
8 |
|i Print version:
|t Neurotransmitters.
|b 1st ed.
|d Oxford ; New York : Pergamon Press, 1979
|w (DLC) 78040989
|w (OCoLC)4593210
|
830 |
|
0 |
|a Advances in pharmacology and therapeutics ;
|v v. 2.
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780080231921
|z Texto completo
|